The invention provides assays and methods for detecting and monitoring systemic inflammation Particularly, the invention in embodiments thereof relates to the use of urinary biomarkers for non-invasive determination of the level of inflammation.

Described herein are methods and compositions for treating or preventing an allergy or anaphylaxis. Certain aspects of the invention relate to administering to a subject an agent that inhibits RELMβ.

Type 1 diabetes (T1D) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of T1D, including the antigens MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3.

A method for collection and dissemination of biologic data, comprising collecting at least one biologic sample by a testing device including thereon an alignment target and including a plurality of immunoassay test strips, wherein the at least one biologic sample contacts a sample pad on at least one of the plurality of immunoassay test strips, assigning correlative values as test results, wherein each test performed on the biologic sample is assigned a different correlative value, receiving the test results at a server disposed on a network, wherein the server has configured thereon a database, assigning a unique identification to the biologic sample, storing the unique identification in the database, storing the test results in the database in association with the unique identification of the biologic sample, and providing access to the database to healthcare organizations for analysis of the test results.

According to an immunochromatographic device for detecting a substance to be detected contained in a detection target in an analyte which is characterized in that a nitrous acid compound containing member having a part containing a nitrous acid compound; a labeling substance retaining member having a labeling substance containing part; an acid anhydride containing member having a part containing an acid anhydride having vapor pressure at 25° C. of 5×10.sup.−2 Pa or less; and a chromatography medium member having a detection part are arranged in a manner that a sample develops in the members in this order, the storage stability can be improved; detection with high sensitivity is possible; and the complexity of production can be reduced.

The present invention generally relates to novel biomarkers and their methods of use for identifying and treating e-cigarette, or vaping, product use-associated lung injury (EVALI).

A Raman Testing System and Method is disclosed that uses chemical analysis to detect the chemical signature of the proteins and nucleic acids associated with pathogens coupled with machine learning to adjust to existing and potential variants of the pathogen.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The present disclosure provides a diabetes mellitus therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a therapy for diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus, said therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a diagnosis of diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus or a risk of the same, said diagnosis using abnormal stem cells as an index. In one embodiment, the abnormal stem cells described in the present disclosure are abnormal hematopoietic stem cells. In one embodiment, CD106 is expressed in the abnormal stem cells described in the present disclosure at a level different from in normal cells.

An object of the present invention is to provide a method for measuring respiratory sensitization and a respiratory sensitization measuring reagent that can be used to evaluate a test substance for respiratory sensitization without using an animal. According to the present invention, there is provided a method for measuring respiratory sensitization, including reacting a N-(arylalkylcarbonyl)cysteine with a test substance; reacting an α-N-(arylalkylcarbonyl)lysine with the test substance; detecting the amount of each of the above compounds or a product thereof after the reaction by optical measurement; and determining respiratory sensitization from the ratio of the reactivity of the α-N-(arylalkylcarbonyl)lysine with the test substance to the reactivity of the N-(arylalkylcarbonyl)cysteine with the test substance or from the reactivity of the α-N-(arylalkylcarbonyl)lysine with the test substance.